ATE473006T1 - Beschichtete teilchenförmige cefuroximeaxetil- zusammensetzungen - Google Patents

Beschichtete teilchenförmige cefuroximeaxetil- zusammensetzungen

Info

Publication number
ATE473006T1
ATE473006T1 AT02777359T AT02777359T ATE473006T1 AT E473006 T1 ATE473006 T1 AT E473006T1 AT 02777359 T AT02777359 T AT 02777359T AT 02777359 T AT02777359 T AT 02777359T AT E473006 T1 ATE473006 T1 AT E473006T1
Authority
AT
Austria
Prior art keywords
cefuroximeaxetil
compositions
coated particle
masked
decomposing
Prior art date
Application number
AT02777359T
Other languages
German (de)
English (en)
Inventor
Matilde Fernandez
Emilio Garriz
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE473006T1 publication Critical patent/ATE473006T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
AT02777359T 2001-11-23 2002-11-21 Beschichtete teilchenförmige cefuroximeaxetil- zusammensetzungen ATE473006T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01500277 2001-11-23
PCT/EP2002/013150 WO2003043638A1 (en) 2001-11-23 2002-11-21 Coated particulate cefuroxime axetil compositions

Publications (1)

Publication Number Publication Date
ATE473006T1 true ATE473006T1 (de) 2010-07-15

Family

ID=8183502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02777359T ATE473006T1 (de) 2001-11-23 2002-11-21 Beschichtete teilchenförmige cefuroximeaxetil- zusammensetzungen

Country Status (34)

Country Link
US (1) US20030161888A1 (enExample)
EP (1) EP1446126B1 (enExample)
JP (1) JP3497503B2 (enExample)
KR (1) KR100979328B1 (enExample)
CN (1) CN1297274C (enExample)
AT (1) ATE473006T1 (enExample)
AU (2) AU2002302147B2 (enExample)
BE (2) BE1015217A5 (enExample)
BR (1) BR0204767A (enExample)
CA (1) CA2408198C (enExample)
CH (1) CH693982A5 (enExample)
CO (1) CO5580783A2 (enExample)
CY (1) CY1110778T1 (enExample)
CZ (1) CZ12993U1 (enExample)
DE (3) DE10254412A1 (enExample)
DK (1) DK1446126T3 (enExample)
ES (2) ES2201932B2 (enExample)
FR (1) FR2832635B1 (enExample)
GB (1) GB2383536B (enExample)
GR (1) GR1004522B (enExample)
HR (2) HRP20020923A2 (enExample)
HU (1) HUP0204026A3 (enExample)
IL (2) IL161972A0 (enExample)
IT (1) ITMI20022470A1 (enExample)
MX (1) MXPA02011561A (enExample)
NO (1) NO335273B1 (enExample)
NZ (1) NZ533092A (enExample)
PL (1) PL205325B1 (enExample)
PT (1) PT1446126E (enExample)
RU (1) RU2241460C2 (enExample)
SI (1) SI1446126T1 (enExample)
TR (1) TR200202559A2 (enExample)
WO (1) WO2003043638A1 (enExample)
ZA (1) ZA200209473B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP2258349B1 (en) 2004-05-11 2014-07-16 Egalet Ltd. Swellable dosage form comprising gellan gum
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP2012107060A (ja) * 2004-12-15 2012-06-07 Aska Pharmaceutical Co Ltd イソソルビドの苦味が軽減された経口製剤及びその製造方法
JP4972311B2 (ja) * 2004-12-15 2012-07-11 あすか製薬株式会社 イソソルビドの苦味が軽減された経口製剤及びその製造方法
DE102005019458A1 (de) * 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术(石家庄)有限公司 一种微囊化头孢呋辛酯的药物组合物
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
CN101756906B (zh) * 2009-11-02 2011-11-16 严洁 盐酸头孢卡品酯颗粒的药物组合物及其制备方法
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
EP2566458B1 (en) 2010-05-04 2015-08-05 Mahmut Bilgic Pharmaceutical formulations compising cefuroxime axetil
JP5853461B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
WO2013024373A1 (en) 2011-08-12 2013-02-21 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
IN2014CN02850A (enExample) 2011-10-31 2015-07-03 Glaxosmithkline Intellectual Property Ltd
CN108338936A (zh) * 2017-01-23 2018-07-31 刘全忠 敏感皮肤防护露的制备及使用
JP2023146766A (ja) * 2022-03-29 2023-10-12 味の素株式会社 造粒物およびその製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
CA1094545A (en) * 1976-02-16 1981-01-27 Michael Gregson Cephalosporin antibiotics
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8320520D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4992276A (en) * 1988-12-14 1991-02-12 Warner-Lambert Company Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same
EP0670716B1 (en) * 1992-11-30 2003-03-26 Kv Pharmaceutical Company Tastemasked pharmaceutical materials
AU6774694A (en) * 1993-04-26 1994-11-21 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
IT1277426B1 (it) * 1995-08-03 1997-11-10 Acs Dobfar Spa Forma cristallina biodisponibile del cefuroxima axetil
NZ299077A (en) * 1996-07-26 1998-06-26 Apotex Inc Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf
DE69730982T2 (de) * 1996-10-28 2005-09-01 General Mills, Inc., Minneapolis Einbettung und einkapselung von teilchen zur kontrollierten abgabe
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
GB9726781D0 (en) * 1997-12-19 1998-02-18 Glaxo Group Ltd Pharmaceutical composition
JP2000516263A (ja) 1997-12-29 2000-12-05 ザ、プロクター、エンド、ギャンブル、カンパニー 錠剤組成物
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
HUP0201307A2 (hu) * 1999-06-11 2002-11-28 Ranbaxy Laboratories Limited Ízfedett gyógyszerkészítmények

Also Published As

Publication number Publication date
SI1446126T1 (sl) 2010-10-29
ITMI20022470A1 (it) 2003-05-24
DE10254412A1 (de) 2003-06-12
RU2241460C2 (ru) 2004-12-10
JP2003160493A (ja) 2003-06-03
FR2832635B1 (fr) 2006-04-21
CA2408198C (en) 2004-03-09
EP1446126A1 (en) 2004-08-18
DK1446126T3 (da) 2010-10-11
NO335273B1 (no) 2014-11-03
AU2002338950A1 (en) 2003-06-10
WO2003043638A1 (en) 2003-05-30
GB0227215D0 (en) 2002-12-24
NZ533092A (en) 2006-02-24
BR0204767A (pt) 2003-09-16
PL357259A1 (en) 2003-06-02
ZA200209473B (en) 2003-06-10
GR20020100506A (el) 2003-07-16
NO20042620L (no) 2004-06-22
KR100979328B1 (ko) 2010-08-31
BE1015217A5 (enExample) 2004-11-09
HUP0204026A2 (hu) 2003-08-28
PT1446126E (pt) 2010-09-24
DE20218068U1 (de) 2003-03-27
DE60236952D1 (de) 2010-08-19
CA2408198A1 (en) 2003-02-02
ES2347536T3 (es) 2010-11-02
TR200202559A2 (tr) 2003-06-23
ES2201932A1 (es) 2004-03-16
CH693982A5 (de) 2004-05-28
GB2383536A (en) 2003-07-02
US20030161888A1 (en) 2003-08-28
JP3497503B2 (ja) 2004-02-16
HU0204026D0 (en) 2003-01-28
EP1446126B1 (en) 2010-07-07
CZ12993U1 (cs) 2003-02-10
FR2832635A1 (fr) 2003-05-30
PL205325B1 (pl) 2010-04-30
CY1110778T1 (el) 2015-06-10
GB2383536B (en) 2003-11-19
CN1297274C (zh) 2007-01-31
IL161972A (en) 2009-06-15
HRP20020924A2 (en) 2003-10-31
AU2002302147B2 (en) 2005-01-20
HUP0204026A3 (en) 2004-09-28
ES2201932B2 (es) 2005-03-16
GR1004522B (el) 2004-04-06
CN1421206A (zh) 2003-06-04
IL161972A0 (en) 2005-11-20
MXPA02011561A (es) 2005-07-13
HRP20020923A2 (en) 2003-10-31
KR20050044590A (ko) 2005-05-12
CO5580783A2 (es) 2005-11-30
BE1014078A6 (fr) 2003-03-04

Similar Documents

Publication Publication Date Title
DK1446126T3 (da) Overtrukne partikulære cefuroximaxetil-sammensætninger
HK106191A (en) Pharmaceutical composition
BR9912979B1 (pt) composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
ZA991408B (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
PT1094788E (pt) Dissimulacao do sabor com croscarmelose
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
WO2000047063A3 (en) Combined milk, juice, and cereal grain/polysaccharide blend for consumption and methods for production thereof
GEP20063821B (en) Orodispersible pharmaceutical composition comprising perindopril
WO2003061728A3 (en) Oral administration of interferon-tau
GEP20063820B (en) Orodispersible pharmaceutical composition comprising ivabradine
WO2004009085A3 (en) Taste masked sumatriptan tablets and processes for their preparation
WO1998027832A3 (de) Verwendung von oligosacchariden zur verstärkung der süsskraft und zur geschmacksverbesserung einer acesulfam-k/aspartam-mischung
AU1289300A (en) Diagnosis of gastric and lung disorders
DE69813846D1 (de) Geschmacksmaskierung schlecht schmeckender formulierungen
IL162524A0 (en) Derivatives of (pyridin-3-yl)-1-azabicycloÄ3.2.1Ü octane, their preparation and their terapeutic application
WO1998036732A3 (de) Kombinationspräparat für oral applizierbare antibiotika
GB9910773D0 (en) Novel single unit coated dosage forms that can be used to minimise the effect of food on the absorption of drugs from the gastrointestinal tract
GEP20063819B (en) Orodispersible pharmaceutical composition comprising piribedil
WO2001060344A3 (en) Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections
WO2001007019A3 (en) Use of n-acetyl-cysteine in the treatment of allergic pathologies of the respiratory tract
CA2312072A1 (en) Oil-free popped wild rice cereal
MX9602863A (es) Preparacion farmaceutica en forma de capsula recubierta liberable en la parte inferior del tracto digestivo.
HK1088551A (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
AU2001229434A1 (en) Intra-vascular administration of particles to induce pulmonary hypertension, pulmonary hypertension syndrome, and ascites in animals

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1446126

Country of ref document: EP